Analyzing Alimera Sciences (NASDAQ:ALIM) & Strongbridge Biopharma (SBBP)

Strongbridge Biopharma (NASDAQ: SBBP) and Alimera Sciences (NASDAQ:ALIM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Strongbridge Biopharma and Alimera Sciences, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Strongbridge Biopharma 0 0 3 0 3.00
Alimera Sciences 0 0 3 0 3.00

Strongbridge Biopharma presently has a consensus price target of $14.67, indicating a potential upside of 75.65%. Alimera Sciences has a consensus price target of $4.00, indicating a potential upside of 214.96%. Given Alimera Sciences’ higher possible upside, analysts plainly believe Alimera Sciences is more favorable than Strongbridge Biopharma.

Profitability

This table compares Strongbridge Biopharma and Alimera Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Strongbridge Biopharma N/A -181.90% -38.62%
Alimera Sciences -55.29% N/A -28.43%

Earnings and Valuation

This table compares Strongbridge Biopharma and Alimera Sciences’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Strongbridge Biopharma N/A N/A -$48.59 million ($3.40) -2.46
Alimera Sciences $34.33 million 2.56 -$33.17 million ($0.31) -4.10

Alimera Sciences has higher revenue and earnings than Strongbridge Biopharma. Alimera Sciences is trading at a lower price-to-earnings ratio than Strongbridge Biopharma, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

64.0% of Strongbridge Biopharma shares are owned by institutional investors. Comparatively, 41.8% of Alimera Sciences shares are owned by institutional investors. 14.7% of Alimera Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk & Volatility

Strongbridge Biopharma has a beta of 2.6, suggesting that its share price is 160% more volatile than the S&P 500. Comparatively, Alimera Sciences has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500.

Summary

Alimera Sciences beats Strongbridge Biopharma on 7 of the 11 factors compared between the two stocks.

About Strongbridge Biopharma

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company’s lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing’s syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).

About Alimera Sciences

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company’s product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with our FREE daily email newsletter.

 


Latest News

Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
Trade Rumor: Manny Machado Could Land With Yankees
Trade Rumor: Manny Machado Could Land With Yankees


Leave a Reply

 
© 2006-2018 BBNS.